BioVersys has access to approximately €2 million in non-dilutive funding from the original IMI2 RespiriNTM grant of approximately €5.7 million.
Organizations Involved
PPP Allowance, Health~Holland, Top Sector Life Sciences & Health
Company Description
BioVersys is focused on developing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The company is part of the EU-funded RespiriNTM programme, which explores new targets for anti-mycobacterial compounds and optimizes novel inhibitors for clinical trials.